| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PROS.10231 |
| P953 | full work available at URL | https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpros.10231 |
| https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.10231 | ||
| P698 | PubMed publication ID | 12746834 |
| P2093 | author name string | Akira Komiya | |
| Hiroyoshi Suzuki | |||
| Koichiro Akakura | |||
| Takeshi Ueda | |||
| Tomohiko Ichikawa | |||
| Tatsuo Igarashi | |||
| Haruo Ito | |||
| P2860 | cites work | Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways | Q28212733 |
| Hormone-refractory (D3) prostate cancer: refining the concept. | Q40453963 | ||
| Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway . | Q40905632 | ||
| Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer | Q41072693 | ||
| Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue | Q42490034 | ||
| Low doses of oral dexamethasone for hormone-refractory prostate carcinoma | Q43514503 | ||
| Potential Mechanism for the Effects of Dexamethasone on Growth of Androgen-Independent Prostate Cancer | Q52544620 | ||
| Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma | Q71018169 | ||
| Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma | Q71079510 | ||
| Hormone/Antihormone Withdrawal and Dexamethasone for Hormone‐Refractory Prostate Cancer | Q74423965 | ||
| Characterization of the role of IL-6 in the progression of prostate cancer | Q74587530 | ||
| Incidence and Characteristics of Antiandrogen Withdrawal Syndrome in Prostate Cancer after Treatment with Chlormadinone Acetate | Q77320214 | ||
| Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer | Q78225972 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dexamethasone | Q422252 |
| oncology | Q162555 | ||
| urology | Q105650 | ||
| P304 | page(s) | 106-109 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | The Prostate | Q7758608 |
| P1476 | title | Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin‐6 | |
| P478 | volume | 56 |
| Q39615546 | A sub-pathway-based approach for identifying drug response principal network |
| Q79811481 | Co-expression of interleukin-6 and human growth hormone in apparently normal prostate biopsies that ultimately progress to prostate cancer using low pH, high temperature antigen retrieval |
| Q39909731 | Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer |
| Q47557846 | Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain. |
| Q80828806 | Glucocorticoid administration in antiemetic therapy: is it safe? |
| Q35776921 | Is there a role for chemotherapy in prostate cancer? |
| Q36216910 | Oral low-dose dexamethasone for androgen-independent prostate cancer patients |
| Q57105398 | PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report |
| Q80605220 | Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy |
| Q28278555 | Prostate cancer and the met hepatocyte growth factor receptor |
| Q82430004 | Retrospective Analysis of an Oral Combination of Dexamethasone, Uracil plus Tegafur and Cyclophosphamide for Hormone-refractory Prostate Cancer |
| Q34467551 | Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer |
| Q60918190 | The Role of Glucocorticoid Receptor Signaling in Bladder Cancer Progression |
| Q39347702 | Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines |
Search more.